Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson's disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and 5HT2C/5HT2B serotonergic antagonist. The aim of this case series was to evaluate the role of agomelatine in the treatment of MDD associated with PD.
Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series
MARTINOTTI, Giovanni;ONOFRJ, Marco;DI GIANNANTONIO, Massimo
2013-01-01
Abstract
Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson's disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and 5HT2C/5HT2B serotonergic antagonist. The aim of this case series was to evaluate the role of agomelatine in the treatment of MDD associated with PD.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
DeBerardis_2013.pdf
Solo gestori archivio
Tipologia:
Documento in Post-print
Dimensione
435.93 kB
Formato
Adobe PDF
|
435.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
